Multiple Sclerosis

Investigational targeted B-cell therapy demonstrates superior efficacy compared with teriflunomide, a commonly prescribed treatment for MS.

Researchers highlight how a lack of access to medications used to treat multiple sclerosis, migraines, and epilepsy, but not proven safe for pregnancy, threatens child-bearing aged women who live with these conditions.

After 4 years of treatment with ofatumumab, 78.8% of patients with relapsing forms of multiple sclerosis who continuously received ofatumumab achieved NEDA-3 compared to 51.8% of those who switched from teriflunomide to ofatumumab.

Jazz Pharmaceuticals announced top-line results from the phase 3 RELEASE MSS1 trial, evaluating nabiximols oromucosal spray in individuals with multiple sclerosis.

Pharmacists should review the medications of patients with multiple sclerosis regularly to assess drug-drug interactions.

Pharmacists who educate patients with multiple sclerosis and expand their understanding and knowledge of the condition empowers them to take part in a more active role in managing their health.

New validated testing method for multiple sclerosis measures kappa immunoglobulin free light chains in cerebrospinal fluid.

Individuals with multiple sclerosis should follow vaccine guidelines before starting disease-modifying therapies, case study results show.

The agency has also approved the baclofen oral suspension for Azurity Pharmaceuticals to treat individuals with other spinal cord diseases or injuries.

The researchers projected that approximately 14 participants would experience a significant worsening of their walking function, however, only 8 participants had their walking function decline.

Study results suggest that infection with Epstein-Barr virus may be the leading cause of multiple sclerosis.

Inhibiting the activity of group 3 innate lymphoid cells could serve as a new therapeutic approach for neurologic conditions.

Agency gives green light to supplemental new drug application for repository corticotropin injection.

According to the investigators, these new data support ofatumumab as a first-choice treatment for adult patients with RMS, including those who are newly diagnosed.

Early intervention with ocrelizumab resulted in a 35% reduction of risk in individuals with RMS who needed a walking aid over 7 and a half years.

The 5 largest specialty therapeutic groups—oncology, autoimmune, immunology, HIV, and multiple sclerosis—will account for 74% of specialty spending growth over the next five years.

Although there was a numerical difference between the mean number of new or newly enlarging T2 hyperintense lesions at week 72 of 0.05 (Q4W) and 0.20 (Q6W), this difference was not clinically meaningful in the context of the full data, according to the investigators.